The focus on dilution is misguided. Once the company starts to rev up the R&D and new filings, future growth to bolster the stellar revenue stream from the Adderall products will propel this stock much higher. A major announcement prior to the August conference would mot surprise me.
Market Data 
Markets 
AI
